UAE announces official registration of China's inacctivated COVID-19 vaccine

The UAE’s Ministry of Health and Prevention (MOHAP) has announced the official registration of the Beijing Institute of Biological Products' inactivated COVID-19 vaccine, in a major step towards combating the global pandemic.

The decision is in response to the application from Sinopharm CNBG.

The announcement is a significant vote of confidence by the UAE’s health authorities in the safety and efficacy of the vaccine.

MOHAP in collaboration with Department of Health Abu Dhabi (DOH) has reviewed Sinopharm CNBG’s interim analysis of the Phase III trials.

This shows the Beijing Institute of Biological Products' inactivated vaccine has 86 per cent efficacy against the COVID-19 virus.

The analysis also shows the vaccine to have 99 per cent seroconversion rate of neutralising antibodies and 100 per cent effectiveness in preventing moderate and severe cases of the disease. Furthermore, the analysis shows no serious safety concerns.

This vaccine has been granted Emergency Use Authorisation since September by MOHAP to protect frontline workers who most at risk of COVID-19.

The UAE is conducting Post Authorisation Safety Study (PASS) and Post Authorisation Efficacy Study (PAES) of its EUA programme. These ongoing studies show similar safety and efficacy profiles as the interim analysis.

The #4Humanity phase III trials have included 31,000 volunteers across 125 nationalities in the UAE alone.

MOHAP's official registration of Beijing Institute of Biological Product’s inactivated COVID-19 vaccine leads the way to comprehensively protecting the population and responsibly opening the economy.